Moleculin Biotech, Inc. (MBRX) announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific conferences in September 2026. The presentations will highlight Annamycin's mechanism of action, tissue concentration, and antitumor activity, including its potential application in pancreatic cancer.
Key Details
- Event: Data will be presented at three scientific venues, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer held from September 25-28, 2026.
- Data Focus: The presentations will detail where Annamycin concentrates in the body (organotropism), how it targets and kills cancer cells, and its ability to activate an immune response against tumors.
- Pancreatic Cancer Presentation: The AACR presentation is titled, "Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity," suggesting a focus on its immunotherapeutic effects in hard-to-treat cancers.